We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Prednisone administration in inflammatory cardiomyopathy: caveat for potentially adverse myocardial actions.
- Authors
Frustaci, Andrea; Russo, Matteo Antonio; Chimenti, Cristina
- Abstract
This commentary refers to 'Immunosuppressive therapy in virus-negative inflammatory cardiomyopathy: 20-year follow-up of the TIMIC trial', by C. Chimenti I et al i . https://doi.org/10.1093/eurheartj/ehac348 and the discussion piece 'Prednisone for inflammatory cardiomyopathy: more than just an immunosuppressive agent', by Z. Yang I et al i . https://doi.org/10.1093/eurheartj/ehad068. We thank Chao Liu and co-authors for contributing in their report ' B Prednisone in inflammatory cardiomyopathy: more than just an immunosuppressive agent b ' to clarify the molecular pathway that make prednisone, in addition to its immunosuppressive and anti-inflammatory action, an agent able to improve both renal and cardiac function. These considerations led us to reduce prednisone administration in our TIMIC protocol applied to inflammatory cardiomyopathy patients from 1 mg/Kg to 0.33 mg/Kg after the first 4 weeks of therapy lasting 6 months.[4] In conclusion a careful balance between positive and unfavorable effects of prednisone administration has to be considered in its chronic use.
- Subjects
CARDIOMYOPATHIES; PREDNISONE; HEART dilatation; CUSHING'S syndrome
- Publication
European Heart Journal, 2023, Vol 44, Issue 15, p1376
- ISSN
0195-668X
- Publication type
Article
- DOI
10.1093/eurheartj/ehad069